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Coenzyme Q10 (CoQ10) concentration in blood cells was analyzed by HPLC and compared to plasma concen-
tration before, during, and after CoQ10 (3 mg/kg/day) supplementation to human probands. Lymphocyte DNA 
8-hydroxydeoxy-guanosine (8-OHdG), a marker of oxidative stress, was analyzed by Comet assay. 
Subjects supplemented with CoQ10 showed a distinct response in plasma concentrations after 14 and 28 days. 
Plasma levels returned to baseline values 12 weeks after treatment stopped. The plasma concentration increase 
did not affect erythrocyte levels. However, after CoQ10 supplementation, the platelet level increased; after sup-
plementation stopped, the platelet level showed a delayed decrease. A positive correlation was shown between 
the plasma CoQ10 level and platelet and white blood cell CoQ10 levels. During CoQ10 supplementation, delayed 
formation of 8-OHdG in lymphocyte DNA was observed; this effect was long-lasting and could be observed even 
12 weeks after supplementation stopped. Intracellular enrichment may support anti-oxidative defense mecha-
nisms. 
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1.  Introduction 
Coenzyme Q10 (CoQ10) is a fat-soluble, vita-
min-like, ubiquitous compound that functions as an 
electron carrier in the mitochondrial respiratory chain, 
as well as serving as an important intracellular anti-
oxidant. CoQ10 protects phospholipids and mito-
chondrial membrane proteins from peroxidation and 
protects DNA against the oxidative damage that ac-
companies lipid peroxidation [1, 2, 3]. Clinical interest 
in CoQ10 analysis and its therapeutic effects is grow-
ing. Several clinical trials and case series have pro-
vided evidence supporting the use of CoQ10 in the 
prevention and treatment of various disorders [4, 5, 6, 
7]. However, in contrast to other lipophilic antioxi-
dants, endogenous synthesis, as well as food intake, 
contributes to CoQ10 levels [8]. Since tissue levels of 
CoQ10 may depend mainly on de novo synthesis [9], it 
is uncertain whether an extracellular supply of CoQ10 
via the circulation could influence intracellular targets 
or exert a protective effect against oxidative DNA 
damage. 
To allow for routine clinical investigation of in-
tracellular CoQ10 concentrations, the authors focused 
on blood cells that could be easily isolated from small 
blood volumes. The present study was designed to 
elucidate the acute and long-term effects of in vivo 
CoQ10 enrichment in the plasma, to shed light on the 
incorporation of the antioxidant into blood cells, and to 
determine its effect on DNA damage in human lym-
phocytes. 
2.  Materials and Methods 
Subjects and sample collection 
Ten female subjects (hospital staff members 
without any known diseases; average age 39 years; age 
range: 30-47 years) were given nanodispersed CoQ10 
(Sanomit® Q10, Monopreparation, MSE, Bad Homburg, 
Germany) in a dose of 3 mg/kg body weight, which 
was taken in the morning and evening for a total of 28 
d a y s .  F r o m  e a c h  s u b j e c t ,  2  m l  v e n o u s  E D T A  b l o o d  
were collected to analyze CoQ10 levels in erythrocytes 
and platelets, another 2 ml of venous blood were col-
lected to evaluate DNA strand breaks in lymphocytes 
using the Comet assay, and 1 ml of venous heparinized 
blood was collected for analysis of plasma CoQ10 lev-
els. The first set of samples was taken following an 
overnight fast, one hour before the first CoQ10 sup-
plementation was taken. A second set of blood sam-
ples was taken after 14 days of supplementation, and a 
third set was taken after 28 days of supplementation in 
the morning following the last CoQ10 dose, which was 
taken the prior evening. A fourth set of blood samples 
was taken 12 weeks after the last dose had been taken 
(day 112). 
In order to obtain more information about the 
effect of CoQ10 supplementation on white blood cell 
concentrations, 10 healthy subjects (3 males, 7 females; 
average age: 40 years; age range: 32-47 years) received 
CoQ10 as described above for a total of 14 days. From Int. J. Biol. Sci. 2007, 3 
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each of them, 2 ml venous EDTA blood was collected 
to analyze CoQ10 levels in platelets and white blood 
cells, and 1 ml venous heparinized blood was collected 
for analysis of plasma concentrations. The first set of 
samples was taken following an overnight fast in the 
morning, one hour before the first CoQ10 dose. A 
second set of blood samples was taken after 14 days of 
supplementation in the morning following the last 
CoQ10 dose, which was taken the prior evening. 
The study was approved by the Human Ethics 
Committee of the Medical Faculty of Witten-Herdecke 
University. 
Sample preparation and analysis 
When blood is collected into tubes with EDTA, 
the redox status of CoQ10 shifts in favour of the oxi-
dized part during sample preparation. Therefore, to 
simultaneously measure the oxidized and reduced 
form of CoQ10 in the plasma, heparinized blood was 
collected; 100 µl aliquots of plasma were stored at 
–84oC until analysis of CoQ10 by HPLC [10]. Ten µl 
samples were stored at -84oC until cholesterol level 
analysis was performed (CHOD-PAP-method, Human, 
Wiesbaden, Germany). 
To analyze CoQ10 levels in blood cells, 2 ml of 
venous EDTA blood was carefully placed above 2 ml 
Ficoll separating solution (Ficoll, Biochrom KG, Berlin, 
Germany). After centrifugation (1000 g, 12 min, braked 
softly), the red blood cell layer at the bottom of the 
tube was removed by aspiration and washed three 
times with 0.9% sodium chloride (centrifugation at 
2500 g, 10 min.). The final erythrocyte suspension was 
adjusted to a hematocrit of about 50%; 230 µl of the 
suspension were used to determine the number of cells 
present (Beckman Coulter, Gen.S, Krefeld, Germany). 
The number of white blood cells and platelets within 
the cell preparation was shown to be negligible. 100 µl 
aliquots of the erythrocyte suspension were stored at 
–84oC, and the CoQ10 levels were determined within 
one week using HPLC as previously described [11]. 
The platelets and white blood cells in the inter-
mediate layer of the Ficoll gradient were removed by 
aspiration and washed in 4 ml PBS (Biochrom KG, 
Berlin, Germany). Centrifugation at 250 g for 12 min-
utes separated the platelets (in the supernatant) from 
the white blood cells (in the pellet). The supernatant 
was transferred into a separate tube and then centri-
fuged at 2200 g for 12 minutes. The pellet was 
re-dissolved in 0.9% sodium chloride; 230 µl of this 
suspension were used to determine the number of cells 
present. The number of remaining red and white blood 
cells within the cell preparation was found to be neg-
ligible. One 100 µl aliquot was stored at –84oC until 
analysis of CoQ10 levels using HPLC [12]. 
The white blood cell fraction (in the pellet after 
the first centrifugation step) was re-dissolved in 500 µl 
0.9% sodium chloride; 230 µl of this suspension were 
used to determine the number of cells present. The 
number of red blood cells within the cell preparation 
was shown to be negligible; however, the white blood 
cell fractions were always contaminated by platelets, 
and this contamination could not be eliminated by 
further washing steps. Therefore, the platelet-portion 
of the CoQ10 level within the white blood cell fraction 
(average 27%) was calculated and then subtracted. 
Two 100 µl aliquots of the suspension were stored at 
–84oC until analysis of the CoQ10 level by the dou-
ble-determination method. 
The CoQ10 level in blood cells was measured 
using HPLC with electrochemical detection and in-
ternal standardization according to a previously pub-
lished method [11, 12]. As an internal standard, 23 
pmol of ubihydrochinone-9 plus 3 pmol ubiquinone-9 
(Sigma, Deisenhofen, Germany) in 50 µl ethanol were 
added to a 100 µl platelet and white blood cell suspen-
sion, and 33 pmol ubiquinone-9 in 50 µl ethanol were 
added to a 100 µl erythrocyte suspension. The cells 
were disintegrated by adding cold methanol, extracted 
with hexane, and evaporated under a stream of argon. 
The dry residue was re-dissolved in 40 µl ethanol and 
injected into the HPLC system. 
To detect 8-OHdG (8-hydroxydeoxy-guanosine), 
a marker of oxidized DNA, so as to quantify oxidative 
damage present in the lymphocytes, single cell gel 
electrophoresis (Comet assay) was used, adapted from 
Singh and co-workers [13] and Collins [14]. 100 µl of 
fresh isolated EDTA-blood samples were mixed with 
100 µl of cell culture freezing medium (GIBCO) and 
stored at -80°C. To analyze 8-OHdG, 3 µl aliquots were 
mixed with warm, low melting point agarose and 
plated on agarose-coated glass slides, which were then 
topped with cover slides. After congealing at +4°C the 
plated glass slides were incubated in the dark for 1 h in 
lysis buffer (2.5 M NaCl, 01 M EDTA, 10 mM Tris, 1% 
Triton X-100, pH 10.0). After washing in reaction 
buffer (40 mM Hepes pH 8.0, 0.1 M KCl, 0.5. mM 
EDTA, 0.2 mg/ml BSA), the plated glass slides were 
incubated at 37°C in the dark for 30 min with forma-
midopyrimidin DNA glycosylase and then for 25 min 
in TBE buffer. Following electrophoresis (25 V, 300 mA, 
25 min) the plated glass slides were washed 3 times for 
5 minutes in 70% ethanol and silver-stained (Silver 
Staining Kit, TREVIGEN). The analysis of resulting tail 
moments of the DNA comets was done microscopi-
cally by rating 100 cells per sample, as per Singh and 
co-workers [13]. 
Statistical methods 
Data are expressed as mean ± SDM. Statistical 
analysis was performed using ANOVA (LSD method); 
correlations were analyzed using Spearman rank cor-
relation.  
3.  Results 
The analysis of CoQ10 levels after oral supple-
mentation in healthy female subjects revealed a sig-
nificant response after 14 days of supplementation 
[Table 1]. Continuing CoQ10 supplementation for an-
other 14 days led to a slight, though not significant, 
further increase. Twelve weeks after the last CoQ10 
dose, plasma CoQ10 concentration had returned to 
baseline values. The plasma CoQ10 concentration de-
pends on the concentration of lipoproteins that act as 
carriers of lipophilic molecules, such as CoQ10. How-Int. J. Biol. Sci. 2007, 3 
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ever, a significant increase in the plasma CoQ10 con-
centration was also found after adjustment for lipid 
levels.  Following an increase in the plasma CoQ10 
concentration, the oxidized part of the total concentra-
tion decreased. While oral supplementation did not 
affect erythrocyte concentrations, CoQ10 supplemen-
tation significantly increased platelet CoQ10 levels 
after 14 days of supplementation, and to a further 
(though not statistically significant) increase after 28 
days of supplementation. Twelve weeks after supple-
mentation ended, platelet CoQ10 concentration again 
decreased, but not to the same extent as the plasma 
CoQ10 concentration. When all of the platelet/plasma 
pairs were correlated independently from the time of 
measurement, a positive correlation between the 
plasma concentration and the platelet concentration of 
CoQ10 (Spearman rank correlation co-efficient, r=0.7, 
p<0.00001; n=40) was found. In platelets, the oxidized 
part of CoQ10 of the total concentration decreased 
with increasing total concentrations. The Comet assay 
did not identify a decrease in the 8-OHdG content in 
lymphocyte DNA until 28 days of CoQ10 supplemen-
tation; however, a decrease in the 8-OHdG content in 
lymphocyte DNA could be observed even 12 weeks 
after the termination of supplementation. 
In the mixed-gender treatment group, oral CoQ10 
supplementation led to a significant increase in plasma 
and platelet CoQ10 levels after 14 days of supplemen-
tation. As well, it was found that increased plasma 
CoQ10 levels were linked to CoQ10 incorporation into 
white blood cells [Figure1].  When all blood 
cell/plasma pairs were correlated independently from 
the time of measurement, a positive correlation be-
tween plasma CoQ10 concentration and platelet 
CoQ10 content (Spearman rank correlation co-efficient, 
p<0.001, n=20) as well as plasma and white blood cell 
CoQ10 concentration (Spearman rank correlation 
co-efficient, p<0.05, n=20) was found [Figure 2]. 
 
Table 1: Coenzyme Q10 in healthy female subjects before (day 
0), during supplementation (day 14, day 28) with Sanomit Q10 
(3 mg/kg/day), and 12 weeks after the last oral dose (day 112). 
Data are expressed as mean ± SDM (n=10). Statistical analysis 
was performed by ANOVA (LSD method; *p<0.05). 
CoQ10 supple-
mentation 
Day 0  Day 14  Day 28  Day 112 
Plasma CoQ10 
(µmol/L) 
 
1.02±0.30 3.93±1.29* 4.11±1.08* 1.12±0.30
Plasma CoQ10 
lipid-related 
(µmol Q10/mol 
chol) 
243±68 941±215* 865±168* 224±56 
Plasma CoQ10 
redox-status 
(%Q10oxidized in 
Q10total) 
10.2±4.1 5.8±1.6* 6.1±1.9* 7.5±0.9* 
Erythrocyte 
CoQ10 
(pmol/cells 
x109) 
32.8±8.8 33.3±10.4 34.8±12.0 34.0±12.2
Platelet CoQ10 
(pmol/cells 
x109) 
190±57 374±224* 441±156* 256±57 
Platelet CoQ10 
redox-status 
(%Q10oxidized in 
Q10total) 
19.8±6.6 14.0±4.6* 14.9±3.8* 17.8±5.4 
Comet-Assay 
(tail moment) 
1.47±0.23 1.48±0.13 1.29±0.13* 1.24±0.17*
 
 
 
 
 
 
Fig. 1: Coenzyme Q10 levels in plasma, platelets, and white blood cells (WBC) of healthy subjects before and after 14 days of 
supplementation with Sanomit
® Q10 (3 mg/kg/day). Data are expressed as mean±SDM (n=10). Statistical analysis was performed by 
ANOVA (LSD method, p<0.05). Int. J. Biol. Sci. 2007, 3 
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Fig. 2: Total Coenzyme Q10 concentrations in platelets and white blood cells correlated to total plasma CoQ10 concentration 
(Spearman rank correlation). 
4.  Discussion 
The bioenergetic property of coenzyme Q10 
combined with its function as an important lipophilic 
antioxidant makes CoQ10 unique. The CoQ10 content 
of organs and membranes depends on their functional 
requirements and exhibits great variations not only in 
different tissues but also within the same organ and 
among individual cell membranes [15]. Decreased 
blood and tissue CoQ10 concentrations have been re-
ported in various disease processes [5, 8]. The results 
of several clinical trials and case series support the use 
of CoQ10 in the prevention and treatment of various 
disorders, such as congestive heart failure [16, 17], 
Parkinson’s disease [18, 19], and breast cancer [20, 21]. 
However, it is uncertain whether a CoQ10 deficiency is 
the cause or the effect of disease. Since CoQ10 comes 
from food intake and endogenous synthesis, the ques-
tion has arisen whether tissue levels can be influenced 
by exogenous supply or are regulated predominantly 
by endogenous synthesis. The routine clinical assess-
ment of CoQ10 status is generally based on plasma 
measurements. As plasma concentrations may not 
adequately represent cellular concentrations, other 
suitable targets that can act as surrogates for tissue 
CoQ10 levels have to be found. The establishment of 
routine clinical assessment of intracellular CoQ10 lev-
els requires easy access to small amounts of material. 
Blood cells fulfill these requirements, and they allow 
intracellular CoQ10 levels to be compared to plasma 
levels. Another reason to choose blood cells as targets 
for determining intracellular CoQ10 levels may be the 
different characteristics of the various blood cells; 
mature erythrocytes and platelets have no nuclei, 
while platelets have mitochondria, and white blood 
cells have nuclei. Differences in incorporation of 
CoQ10 into these cells may suggest intracellular tar-
gets. 
The present study compared CoQ10 levels in 
various blood cells and in their external environment 
in healthy adult subjects before, during, and after oral 
CoQ10 supplementation. The baseline CoQ10 levels in 
blood cells were in agreement with previously re-
ported data [22]. The effect of CoQ10 supplementation 
on DNA strand breakdown in lymphocytes was ana-
lyzed. In this part of the study, only female subjects 
were included because our Comet assay may be more 
effective in females (unpublished data). 
In agreement with previous findings [11, 12] in 
healthy subjects, an excessive level of nanodispersed 
CoQ10 can be achieved by the oral administration of 
high doses of CoQ10 (3 mg/kg/day); subjects given 
CoQ10 had distinct but individually different increases 
in plasma CoQ10 concentrations. As expected, 12 
weeks after supplementation was stopped, plasma 
concentrations returned to baseline values. The plasma 
half-life of CoQ10 is about 33 hours [8]. In the circula-
tion, CoQ10 is carried by lipoproteins and is primarily 
bound to LDL. A significant increase in plasma CoQ10 
concentration following oral supplementation was also 
found when the plasma concentrations were normal-
ized to the lipid content; this shows that lipoproteins 
posses a residual binding capacity for orally adminis-
tered CoQ10. In agreement with previous reports 
[11,12], the present study found a decrease in the oxi-
dized portion of CoQ10 at increasing total plasma 
concentrations.  
As has been previously demonstrated [11, 12], 
high plasma CoQ10 levels did not affect red blood cell 
CoQ10 concentrations in healthy adults. In-
ter-individual differences in erythrocyte CoQ10 con-
tent were independent of the cell volume and were 
found to be stable. A low erythrocyte CoQ10 level has 
been reported in schizophrenic patients [23]. However, 
in patients suffering from sickle cell anemia - a genetic 
anemia characterized by an overall accelerated pro-
duction of reactive oxygen species – the CoQ10 eryth-
rocyte concentrations were found to be dramatically 
elevated in the presence of normal or low plasma 
concentrations [11]. This finding suggests the possibil-
ity that there are discrepancies between extracellular 
and intracellular CoQ10 concentrations. 
Platelet CoQ10 concentrations increased with in-
creasing plasma concentrations during supplementa-Int. J. Biol. Sci. 2007, 3 
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tion. This increase was accompanied by a shift in the 
redox status favoring the reduced part. However, there 
was a delay in the decrease in the platelet CoQ10 con-
centration after supplementation was stopped. 
An excessive supply of CoQ10 may not influence 
the outer cell membrane compartments of erythrocytes 
but may influence intracellular compartments. In the 
present study, the total plasma CoQ10 concentration 
was correlated with the platelet and white blood cell 
CoQ10 concentrations. Since no correlation has been 
demonstrated between plasma and platelet CoQ10 
levels in healthy subjects [12], an interaction between 
blood cell CoQ10 levels and plasma CoQ10 levels may 
be only expected in deficient situations or during ex-
cessive supply. 
Since blood platelets contain mitochondria, they 
are a suitable cellular target for assessing intracellular 
CoQ10 concentrations, especially in patients with 
neurodegenerative or mitochondrial diseases. CoQ10, 
due to its role in mitochondrial electron transport and 
in antioxidant defense, has been proposed as a protec-
tive agent for patients with Parkinson’s disease [18, 19], 
in which both mitochondrial dysfunction and neuronal 
damage due to oxidative free radicals occur. However, 
clinical recommendations with respect to the use of 
CoQ10 in mitochondrial diseases are inconsistent [24, 
25]. Thus, it is necessary to prove that orally supple-
mented CoQ10 is incorporated into intracellular tar-
gets. 
A deficiency in plasma CoQ10 levels has been 
found in various cancer diseases; the potential thera-
peutic benefit of CoQ10 supplementation has been 
discussed [26, 27]. However, the little that is known 
about tissue CoQ10 concentrations in cancer patients is 
contradictory [28, 29]. While serum CoQ10 concentra-
tions of lung carcinoma patients have been reported to 
be decreased, platelet CoQ10 concentrations appear to 
be unaffected [30]. Decreased plasma CoQ10 concen-
trations in cancer patients may be due to an increased 
consumption of this antioxidant by free radicals or 
may be caused by an increased extraction of CoQ10 
from the blood due to increased tumor cell demand. 
The extracellular supply of CoQ10 through the 
circulation influences CoQ10 levels in blood cells. 
However, the mechanism of intracellular incorpora-
tion is not completely understood. The intracellular 
incorporation of lipophilic antioxidants may be linked 
to the cellular incorporation of lipoproteins [31, 32]. 
The different pharmacokinetic characteristics of CoQ10 
in plasma and in blood cells suggests that intracellular 
transport is not a simple diffusion mechanism. 
The experiments of Tomasetti and coworkers [33] 
have shown that in vitro CoQ10 supplementation en-
hances DNA resistance towards H2O2-induced oxida-
tive DNA damage in human lymphocytes. In the pre-
sent study, oral CoQ10 supplementation supported in 
vivo intracellular antioxidative defense mechanisms, as 
inhibition of DNA strand breakdown in lymphocytes 
was demonstrated. Interestingly, it may take several 
weeks of supplementation to achieve this effect. On the 
other hand, once achieved, the effect may be a 
long-term, protective effect that can last for several 
weeks after supplementation is stopped. Since intra-
cellular enrichment with CoQ10 may decrease oxida-
tive damage of lymphocyte DNA in healthy adults, 
this protective effect of CoQ10 may be even more 
marked in pathophysiological conditions present in 
patients suffering from pro-oxidative diseases.   
In conclusion, the oral administration of CoQ10 in 
sufficient doses leads to the incorporation of CoQ10 
into platelets and white blood cells. Thus, blood cells 
may provide suitable targets for assessing intracellular 
CoQ10 concentrations. Intracellular enrichment may 
support cellular antioxidative defense mechanisms.  
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